Press Release – For immediate Release – 5:45 pm CET
Under the liquidity contract entrusted by Median Technologies (FR0011049824 – ALMDT FP) to TP ICAP (Europe), the following resources were listed in the liquidity account as of 12/29/2023:
- 28,228 shares
- €106,617.89 in cash
During the second half of 2023, it has been traded a total of:
| BUY | 96,229 Shares | EUR 457,244.45 | 338 transactions |
| SELL | 96,971 Shares | EUR 461,187.31 | 273 transactions |
At the time of the half-yearly statement of 06/30/2023, the following resources were included in the liquidity account:
- 28,970 shares
- €105,784.53 in cash
When the new liquidity contract was put in place on 05/04/2020, the following resources were made available:
- 4,404 shares
- € 173,829.64 in cash
The daily transaction table is provided in the pdf version of the press release.
TP ICAP (Europe) is authorized and regulated by the Autorité de Contrôle Prudentiel et de Résolution (ACPR) and the Autorité des Marchés Financiers (AMF).
Pioneering in innovative imaging solutions and services, Median Technologies harnesses cutting-edge AI to elevate the accuracy of early cancer diagnoses and cancer treatments. Median’s offerings, including iCRO for medical image analysis and management in oncology trials and eyonis™, AI/ML tech-based suite of software as medical devices (SaMD), empower biopharmaceutical entities and clinicians to advance patient care and expedite novel therapies. The French-based company, with a presence in the U.S. and China is listed on the Euronext Growth market (ISIN: FR0011049824, ticker: ALMDT). Median is eligible for the French SME equity savings plan scheme (PEA-PME).